Literature DB >> 6418858

Dopamine receptor agonists: intrinsic activity vs. state of receptor.

A Carlsson.   

Abstract

Based on observations with the novel dopamine-receptor agonist 3-(3-hydroxyphenyl-)-N-n-propylpiperidine, 3-PPP, especially its levorotatory enantiomer, it is proposed that the intrinsic activity of a receptor agonist depends in part on the responsiveness of the receptor; this in turn is determined by the degree of previous agonist occupancy on the receptor. A change in occupancy will induce a slow conformational change, influencing the responsiveness. This may constitute an important aspect of receptor adaptation and may help to explain otherwise puzzling phenomena, e.g. that compounds such as (-)-3-PPP or transdihydrolisuride can act as strong dopamine-receptor agonists in some locations and as antagonists in others. The observations discussed in the present paper may be interpreted to indicate that the dopamine receptors in different locations are, in fact, derived from a homogenous receptor population, though in a varying state of adaptation. Thus it may prove worth-while to reconsider the various subclassifications of DA receptors proposed so far.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6418858     DOI: 10.1007/BF01249001

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  11 in total

1.  Effects of putative dopamine autoreceptor agonists in pharmacological models related to dopaminergic and neuroleptic activity.

Authors:  J Arnt; A V Christensen; J Hyttel; J J Larsen; O Svendsen
Journal:  Eur J Pharmacol       Date:  1982-12-24       Impact factor: 4.432

2.  3-PPP, a new centrally acting DA-receptor agonist with selectivity for autoreceptors.

Authors:  S Hjorth; A Carlsson; H Wikström; P Lindberg; D Sanchez; U Hacksell; L E Arvidsson; U Svensson; J L Nilsson
Journal:  Life Sci       Date:  1981-03-16       Impact factor: 5.037

Review 3.  Brain dopamine receptors.

Authors:  P Seeman
Journal:  Pharmacol Rev       Date:  1980-09       Impact factor: 25.468

4.  Are "on-off" effects during chronic L-dopa treatment due to faulty feedback control of the nigrostriatal dopamine pathway?

Authors:  A Carlsson
Journal:  J Neural Transm Suppl       Date:  1983

5.  Dual action on central dopamine function of transdihydrolisuride, a 9, 10-dihydrogenated analogue of the ergot dopamine agonist lisuride.

Authors:  H Wachtel; R Dorow
Journal:  Life Sci       Date:  1983-01-24       Impact factor: 5.037

6.  Central dopamine receptor agonist and antagonist actions of the enantiomers of 3-PPP.

Authors:  S Hjorth; A Carlsson; D Clark; K Svensson; H Wikström; D Sanchez; P Lindberg; U Hacksell; L E Arvidsson; A Johansson
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

7.  Dopamine receptors involved in prolactin secretion pharmacologically characterized by means of 3-PPP enantiomers.

Authors:  E Eriksson; K Modigh; A Carlsson; H Wikström
Journal:  Eur J Pharmacol       Date:  1983-12-09       Impact factor: 4.432

8.  On the mode of action of 3-(3-hydroxyphenyl)-N-n-propylpiperidine, 3-PPP, and its enantiomers. With particular reference to dopaminergic mechanisms in the central nervous system.

Authors:  S Hjorth
Journal:  Acta Physiol Scand Suppl       Date:  1983

9.  Dopamine receptor agonistic and antagonistic effects of 3-PPP enantiomers.

Authors:  J Arnt; K P Bøgesø; A V Christensen; J Hyttel; J J Larsen; O Svendsen
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

10.  Pharmacological profiles of the putative dopamine autoreceptor agonists 3-PPP and TL-99.

Authors:  G E Martin; D R Haubrich; M Williams
Journal:  Eur J Pharmacol       Date:  1981-11-19       Impact factor: 4.432

View more
  32 in total

1.  The partial D2-like dopamine receptor agonist terguride acts as a functional antagonist in states of high and low dopaminergic tone: evidence from preweanling rats.

Authors:  Sanders A McDougall; Rita M Hernandez; Carmela M Reichel; Cristal M Farley
Journal:  Psychopharmacology (Berl)       Date:  2004-11-18       Impact factor: 4.530

2.  An evaluation of the partial dopamine agonist terguride regarding positive symptoms reduction in schizophrenics.

Authors:  R Olbrich; H Schanz
Journal:  J Neural Transm Gen Sect       Date:  1991

3.  Effects of (-)-OSU6162 and ACR16 on motor activity in rats, indicating a unique mechanism of dopaminergic stabilization.

Authors:  Johan P Rung; Emilia Rung; Lisa Helgeson; Anette M Johansson; Kjell Svensson; Arvid Carlsson; Maria L Carlsson
Journal:  J Neural Transm (Vienna)       Date:  2008-03-20       Impact factor: 3.575

4.  Evidence for selective inhibition of limbic forebrain dopamine synthesis by 8-OH-DPAT in the rat.

Authors:  S Ahlenius; V Hillegaart; A Wijkström
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-05       Impact factor: 3.000

5.  Differential effects of apomorphine on spinal reflex activity following 6-hydroxydopamine or long-term haloperidol pretreatment.

Authors:  T S Jensen; N J Christensen; D F Smith
Journal:  J Neural Transm       Date:  1986       Impact factor: 3.575

6.  Central 5-HT and the respiratory response to acoustic stimulation in awake rats: effects of PCPA, 5-HTP and 8-OH-DPAT.

Authors:  S Ahlenius; C O Criborn; C Henriksson
Journal:  J Neural Transm       Date:  1985       Impact factor: 3.575

Review 7.  Dopamine-receptor agonists: mechanisms underlying autoreceptor selectivity. I. Review of the evidence.

Authors:  D Clark; S Hjorth; A Carlsson
Journal:  J Neural Transm       Date:  1985       Impact factor: 3.575

8.  Central dopaminergic properties of HW-165 and its enantiomers; trans-octahydrobenzo(f)quinoline congeners of 3-PPP.

Authors:  S Hjorth; K Svensson; A Carlsson; H Wikström; B Andersson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-07       Impact factor: 3.000

9.  Lisuride, LY-141865, and 8-OH-DPAT facilitate male rat sexual behavior via a non-dopaminergic mechanism.

Authors:  S Ahlenius; K Larsson
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

10.  S(-)DP-5,6-ADTN as an in vivo dopamine receptor ligand: relation between displacement by dopamine agonists and their pharmacological effects.

Authors:  H Rollema; M G Feenstra; C J Grol; M H Lewis; L Staples; R B Mailman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-04       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.